D-HF 2018 - Home


December 14  –  15, 2018
Frankfurt, Germany

D-HF 2018: Device Therapies for Heart Failure - D-HF D-HF 2018 Device Therapies for Heart Failure
D-HF 2018

Device Therapies for Heart Failure
December 14 - 15, 2018
Frankfurt, Germany



Please subscribe to our
csi pfeil
newsletter

Add to my calendar

D-HF Abstracts Registration Scientific Faculty Topics Scientific Program Archive Key Information Event Calendar Sponsors
Fontsize bigger
  D-HF 2018: Device Therapies for Heart Failure
D-HF 2018: Device Therapies for Heart Failure

Board of Directors

Horst Sievert, MD

CardioVascular Center Frankfurt CVC
Frankfurt
Germany

Board of Directors: Horst Sievert, MD
More

Horst Sievert, MD

CardioVascular Center Frankfurt CVC
Frankfurt, Germany

Board of Directors: Horst Sievert, MD
Director and Founder of CVC Frankfurt

Specialist in Internal Medicine, Cardiology, Angiology, and Intensive Care

Medical degree from Johannes Gutenberg University Mainz and Johann Wolfgang Goethe University Frankfurt, Germany

Dr. Sievert has been the Principal Investigator of a number of clinical trials and has authored more than 130 manuscripts and 600 abstracts in peer reviewed journals, as well as 70 books and book contributions. He has also delivered more than 600 invited lectures around the world.
 
He has personally performed more than 16,000 PCIs and 6,000 peripheral angioplasties. However, his activity in the cath lab is focused on highly specialized non-coronary interventions for patients with congenital heart disease, carotid disease, or high risk of stroke, among other conditions. Dr Sievert was the first to close the left atrial appendage percutaneously. He has the largest experience worldwide in catheter closure of heart defects in adults and gets referrals from all over the world.

Navin Kapur, MD

Tufts Medical Center
Boston
USA

Board of Directors: Navin Kapur, MD
More

Navin Kapur, MD

Tufts Medical Center
Boston, USA

Board of Directors: Navin Kapur, MD
Dr. Kapur is a dual, board-certified Interventional Cardiologist and Advanced Heart Failure/Cardiac Transplant specialist. He is Executive Director of The CardioVascular Center for Research and Innovation (CVCRI); at Tufts Medical Center; Director of the Interventional Research Laboratories; and Director of the Cardiac Biology Research Program in the Molecular Cardiology Research Institute (MCRI). His clinical expertise focuses on invasive hemodynamics, mechanical circulatory support, and interventional therapies for patients with advanced heart failure. Under his direction, the CVCRI engages with multiple strategic partners and startup companies to accelerate their technologies with a full array of studies ranging from preclinical studies, fundamental biologic discoveries, first in man programs, and clinical trials. Dr. Kapur’s translational research focuses on large animal models of acute and chronic heart failure, device development and testing, and cardioprotective mechanisms in the setting of acute myocardial infarction and heart failure. The CVCRI engages with multiple strategic partners and startup companies to accelerate their technologies with a full array of studies ranging from preclinical studies, fundamental biologic discoveries, first in man programs, and clinical trials. Dr. Kapur’s basic science laboratory focuses on molecular mechanisms governing maladaptive cardiac remodeling in heart failure. Dr. Kapur serves on several national and international committees involved with the American Heart Association, the American College of Cardiology, the Heart Failure Society of America, the Internationsl Society of Heart and Lung Transplantation, and the Society for Cardiac Angiography and Interventions He is the recipient of grant funding from the National Institutes of Health, American Heart Association, and industry sponsors.

Stefan Anker, MD

Charité - Universitätsmedizin
Berlin
Germany

Board of Directors: Stefan Anker, MD
More

Stefan Anker, MD

Charité - Universitätsmedizin
Berlin, Germany

Board of Directors: Stefan Anker, MD
Stefan D. Anker is Professor of (Tissue)Homeostasis in Cardiology & Metabolism (W3) at Charité Berlin (from
June 2017).

Dr. Anker studied medicine at Charité Berlin and completed his clinical training in Germany and
the UK. He obtained his M.D. from Charité Medical School, Berlin, Germany (1993), and his Ph.D. (1998) at
National Heart & Lung Institute of Imperial College London.
He was Professor of Cardiology & Cachexia
Research (W2) at Charité (2002-14), and Professor of Innovative Clinical Trials (W3) in Göttingen (2014-17).
Dr. Anker has authored more than 750 original papers, reviews, and editorials that are well cited (total
citations: >52,000, h-index: 108, papers with ≥ 200 citations: 64; source: Scopus, 22nd Oct, 2017).
For his work Dr. Anker has won several prizes, and obtained a number of fellowships & grants, incl. 2 from
NIH (WARCEF EU), 2 EU-FP7 & 2 IMI/Horizon2020 grants. He was co-ordinator for “SICA-HF” (EU-FP7). He
received grants for three IITs that are currently running for >13 Mill EUR (from DZHK Germany & industries).

Dr. Anker is Vice President of the European Society of Cardiology (ESC, 2016-18), serving on the ESC board
since 2012. Dr. Anker serves in the board of the Heart Failure Association (HFA) of the ESC since 2006; he
was HFA President (2012-14), and currently chairs the HFA committee on regulatory affairs. He is founding
Editor-in-Chief of the first open access heart failure journal ESC Heart Failure. Dr. Anker serves on the
editorial boards of 4 scientific journals (including European Heart Journal and European Journal of Heart
Failure), and he worked in several ESC Guideline task forces.

Dr. Anker is the founding president of the International Society on Sarcopenia, Cachexia and Wasting
Disorders (SCWD – see www.cachexia.org). Dr. Anker is founding Editor-in-Chief of the Journal of Cachexia,
Sarcopenia and Muscle (JCSM, 2016-IF: 9.70, see www.jcsm.info).

Dr. Anker was and is member of >30 international clinical trial steering committees, chairing or co-chairing
several currently (FAIR-HF2, EMPEROR-HFpEF, Fair-HFpEF) as well as in the past (incl. FAIR-HF,
TIM-HF, AUGMENT-HF, IMPULSE-HF & BACH). He served in a number of DMC’s (chairing 4) and
end-point committees (chairing 4).

William T. Abraham, MD

Ohio State University Wexner Medical Center
Columbus, OH
USA

Board of Directors: William T. Abraham, MD
More

William T. Abraham, MD

Ohio State University Wexner Medical Center
Columbus, OH, USA

Board of Directors: William T. Abraham, MD
William T. Abraham, M.D., F.A.C.P., F.A.C.C., F.A.H.A., F.E.S.C., F.R.C.P.
Professor of Internal Medicine, Physiology and Cell Biology
Chair of Excellence in Cardiovascular Medicine
Associate Dean for Clinical Research
Chief, Division of Cardiovascular Medicine
Medical Director, Clinical Trials Management Office
Deputy Director, Dorothy M. Davis Heart and Lung Research Institute
The Ohio State University, Columbus, Ohio

Dr. Abraham earned his medical degree from Harvard Medical School in Boston, Massachusetts,
following which he completed his residency in Internal Medicine and fellowships in
Cardiovascular Disease and Advanced Heart Failure/Transplant Cardiology at the University of
Colorado Health Sciences Center. He previously held leadership positions at the University of
Colorado, the University of Cincinnati, and the University of Kentucky. At the Ohio State
University, Dr. Abraham holds several leadership positions including an Associate Dean position,
managing the College of Medicine’s non-cancer clinical and translational research portfolio. As
Division Director, Dr. Abraham has developed one of the largest and most successful academic
programs of Cardiovascular Medicine in the U.S.

Clinically, Dr. Abraham is board certified in Internal Medicine and Advanced Heart Failure and
Transplant Cardiology. He spends the majority of his clinical time managing heart failure
patients in the inpatient and outpatient settings. Dr. Abraham has been recognized as one of the
“Best Doctors in America” for fourteen consecutive years and is ranked among the top 10% of
physicians nationally in patient satisfaction.

Dr. Abraham’s research program focuses on elucidating basic mechanisms in heart failure and on
clinical drug and device trials in heart failure. Dr. Abraham has received grants from the National
Institutes of Health (NIH) including current NIH funding, the American College of Cardiology,
and the Aetna Quality Care Foundation. He has made major contributions to advancing clinical
science and patient care in heart failure in at least three areas: device development in heart
failure; neurohormonal therapies in heart failure including beta-blockers, natriuretic peptides, and
vasopressin receptor antagonists; and acute heart failure and renal dysfunction complicating heart
failure. His work has contributed to the approval and adoption of several new therapies or
devices for heart failure, including beta-blockers, natriuretic peptides, cardiac resynchronization
therapy, ultrafiltration, implantable hemodynamic monitoring, and transvenous phrenic nerve
stimulation (for co-morbid central sleep apnea).

Faculty

Information will be available soon.


Associated Faculty

Information will be available soon.


Program Committee

John Cleland, MD

Castle Hill Hospital
Kingston-upon-Hull
UK

Hueseyin Ince, MD

Vivantes Hospital Friedrichshain and Vivantes Urban Hospital
Berlin
Germany

Nicolas M. Van Mieghem, MD

Erasmus Medical Center
Rotterdam
The Netherlands

Howard Levin, MD

Coridea
New York City
USA

Felix Mahfoud, MD

Saarland University Hospital
Homburg
Germany

Martin Bergmann, MD

Cardiologicum Hamburg
Hamburg
Germany

CSI   CSI
Contact Data Privacy Imprint Home CSI 2018 Visit us on Facebook Visit us on Twitter